Back to top

Image: Bigstock

Spectrum Pharmaceuticals, Inc.

Read MoreHide Full Article

Spectrum's low product sales remain a cause of concern. Moreover, gaining market share is challenging for Spectrum as it competes with several companies with greater financial strength. However, the company’s lead pipeline candidate, Rolontis, is progressing well. A BLA is expected in 2018 and a potential approval will help the company compete better. However, Spectrum’s efforts to gain approval for Qapzola (bladder cancer) in the U.S. suffered a setback with the FDA issuing a complete response letter (CRL) in Nov 2016. Additional issues on the regulatory/development front could affect the stock. Also, low product sales remain a cause of concern. On the flip side, with the company entering into out-licensing agreements for a number of products, it will now be able to focus on Evomela and the development of its pipeline candidates. Spectrum’s shares have significantly outperformed the industry so far this year.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Spectrum Pharmaceuticals, Inc. (SPPI) - free report >>

Published in